Bay Area-based CytomX and Astellas forged a strategic relationship worth up to more than $1.6 billion to discover and develop novel T-cell engaging bispecific antibodies targeting CD3 and tumor cell surface antigens for the treatment of cancer.
Epizyme’s oral potent, first-in-class EZH2 inhibitor tazemetostat won accelerated approval from the U.S. Food and Drug Administration for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.
The U.S. Food and Drug Administration declined to approve Enzyvant’s regenerative tissue therapy for a rare immunodeficiency disorder and raised concerns about the privately held drug developer’s manufacturing.
Mallinckrodt plc announced positive top-line results from the global biopharmaceutical company’s pivotal Phase 3 clinical trial of the investigational StrataGraft regenerative tissue.
Researchers with the Hubrecht Institute in Utrecht, Netherlands and Radboud University in Nijmegen, Netherlands, developed a human model using organoids to evaluate the function of specific genes commonly mutated in liver cancer.
Boehringer Ingelheim’s SENSCIS Phase III clinical trial met the primary endpoint for nintedanib in patients with SSc-ILD.
Researchers are having a hard time getting their hands on specimens for their work on new treatments, diagnostics, and cures.
A rubbery sea creature with a habit of clinging to ships and invading beaches could help measure plastic pollution, as sea squirts can filter tiny particles from the ocean and store them in their soft tissue.
The miniature robot – the bacteria-inspired brainchild of a team of scientists in Switzerland seeking new methods to deliver drugs to diseased tissue – is designed to wend its way through blood vessels and other systems in the body.
Bristol-Myers Squibb is teaming up with Cancer Research UK and the Francis Crick Institute to create guidelines for immuno-oncology therapy development focused on lung cancer treatments.